Clinical trials targeting neurofibromatoses-associated tumors: a systematic review

Gabriel Roman Souza, Ahmed Abdalla, Daruka Mahadevan

Research output: Contribution to journalArticlepeer-review

Abstract

Background: There is a paucity of literature that comprehensively analyzes previous and current clinical trials targeting neurofibromatoses-related tumors. This article aims to provide readers with drug development efforts targeting these tumors by analyzing translational and clinical findings. Methods: This systematic review was written according to the PRISMA guidelines. Inclusion criteria were clinical trials involving patients with neurofibromatosis type 1, type 2, or schwannomatosis that were treated with therapies targeting neurofibromatoses-associated tumors and that were registered on clinicaltrials.gov. In addition, a search was performed in PubMed, Web of Science, Google Scholar, and Embase European for articles fully describing these clinical trials. Results: A total of 265 clinical trials were registered and screened for eligibility. Ninety-two were included in this systematic review involving approximately 4636 participants. The number of therapies analyzed was more than 50. Drugs under investigation mainly act on the MAPK/ERK and PI3K/AKT/mTOR pathways, tumor microenvironment, or aberrantly over-expressed cell surface receptors. Selumetinib was the most effective medication for treating a neurofibromatosis type 1-associated tumor with approximately 68%-71% partial response for inoperable or progressive plexiform neurofibromas in children 2 years of age and older and bevacizumab for a neurofibromatosis type 2-related tumor with approximately 36%-41% partial response for vestibular schwannomas in patients 12 years of age and older. Conclusions: This systematic review presents the results of previous clinical investigations and those under development for neurofibromatoses-associated tumors. Clinicians may use this information to strategize patients to appropriate clinical trials.

Original languageEnglish (US)
Article numbervdac005
JournalNeuro-Oncology Advances
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2022

Keywords

  • clinical trials
  • neurofibromatosis type 1
  • neurofibromatosis type 2
  • schwannomatosis
  • therapies

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Surgery

Fingerprint

Dive into the research topics of 'Clinical trials targeting neurofibromatoses-associated tumors: a systematic review'. Together they form a unique fingerprint.

Cite this